Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation

Transfusion

Volumn 47, Issue 12, 2007, Pages 2207-2216

  Wang, Shirong ^a   Nademanee, Auayporn ^a   Qian, Dajun ^a   Dagis, Andrew ^a   Park, Hyun Soon ^a   Fridey, Joy ^a   Smith, Eileen ^a   Snyder, David ^a   Somlo, George ^a   Stein, Anthony ^a   Rosenthal, Joseph ^a   Falk, Peter ^a   Kogut, Neil ^a   Palmer, Joycelynne ^a   Gaal, Karl ^a   Kim, Young ^a   Bhatia, Ravi ^a   Yuan, Shan ^a   Kay, Candace ^a   Weiss, Lawrence ^a   Forman, Stephen ^a   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD SAMPLING; CD34 SELECTION; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; SOLID TUMOR; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 36348948442     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01448.x     Document Type: Article

References (48)

1. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998 4 : 311 6.
2. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR, Moreb JS. Poor mobilization of peripheral blood stem cell is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003 44 : 815 20.
3. Nowrousian MR, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cell in cancer patients. Ann Oncol 2003 14 (Suppl 1 i29 36.
4. Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereux S, Goldstone AH, Linch DC. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997 15 : 535 46.
5. Dazzi C, Cariello A, Rosti G, Monti G, Sebastiani L, Argnani M, Nicoletti P, Tienghi A, Leoni M, Fiorentini G, Turci D, Giovanis P, De Giorgi U, Marangolo M. Peripheral blood cell (PBSC) mobilization in heavily pretreated patients with germ cell tumor: a report of 34 cases. Bone Marrow Transplant 1999 23 : 529 32.
6. 2 CY. Bone Marrow Transplant 1999 23 : 421 5.
7. Weaver CH, Schwartzberg LS, Birch R, Greco FA, Rhinehart S, Hainsworth J, Beeker T, Price H, Geier L, Foster J, West J, Hazelton B, Buckner CD. Collection of peripheral blood progenitor cells after the administration of cyclophosphasmide, epoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients. Transfusion 1997 37 : 896 903.
8. Reiser M, Josting A, Draube A, Mapara MY, Scheid C, Chemnitz J, Tesch H, Wolf J, Diehl V, Söhngen D, Engert A. Successful peripheral blood stem cell mobilization with etoposite (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 1999 23 : 1223 8.
9. Solá C, Maroto P, Salazar R, Mesía R, Mendoza L, Brunet J, López-Pousa A, Tabernero JM, Montesinos J, Pericay C, Martínez C, Cancelas JA, López-López JJ. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and Filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999 4 : 195 209.
10. Itoh K, Ohtsu T, Sasaki Y, Ogura M, Morishima Y, Kasai M, Chou T, Yoshida K, Ohno T, Mizorogi F, Uike N, Sai T, Taniwaki M, Ikeda S, Tobinai K. Randomized comparison of mobilization kinetics of circulating CD34+ cells between weekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The Lenograstim/Lymphoma Study Group. Leuk Lymphoma 2000 38 : 521 32.
11. Micallef I, Apostolidis J, Rohatiner A, Wiggins C, Crawley CR, Foran JM, Leonhardt M, Bradburn M, Okukenu E, Salam A, Matthews J, Cavenagh JD, Gupta RK, Lister TA. Factors which predict unsuccessful mobilization of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000 1 : 367 73.
12. Ashihara E, Shimazaki C, Okano A, Hatsuse M, Inaba T, Nakagawa M. Feasibility and efficacy of high-dose etoposide followed by low-dose G-CSF as a mobilization regimen in patients with non-Hodgkin's lymphoma. Haematologica 2000 85 : 1112 4.
13. Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A, Agape P, Nicolini F, Dazey B, Reiffers J, Salmi R, Marit G. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood stem cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001 27 : 837 42.
14. Kanfer EJ, McGuigan D, Samson D, Abboudi Z, Abrahamson G, Apperley JF, Chilcott S, Craddock C, Davis J, MacDonald C, Macdonald D, Olavarria E, Philpott N, Rustin GJ, Seckl MJ, Sekhar M, Stern S, Newlands ES. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cell: efficacy and toxicity at three dose levels. Br J Cancer 1998 78 : 928 32.
15. Bojko P, Scheulen ME, Hilger R, Oberhoff C, Schindler AE, Seeber S. High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. J Cancer Res Clin Oncol 2001 127 : 243 50.
16. Schwartzberg LS, Weaver CH, Birch R, Manner C, Tauer K, Beeker T, Morgan-Ihrig C, MacAneny B, Leff R, Smith R, Hainsworth J, Greco T, Schwerkoske J, Murphy MN, Buckner CD. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood progenitor cells in 318 patients with stage II-III breast cancer. J Hematother 1998 78 : 928 32.
17. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V. Mobilization of peripheral blood stem cell with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002 29 : 285 90.
18. Mollee P, Pereira D, Nagy T, Song K, Saragosa R, Keating A, Crump M. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2002 30 : 273 8.
19. Marit G, Thiessard F, Faberes C, Cony-Makhoul P, Boiron JM, Bernard P, Pigneux A, Puntous M, Agape P, Vezon G, Broustet A, Girault D, Salmi LR, Reiffers J. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 1998 12 : 1447 56.
20. Goldschmidt H, Hegenbart U, Wallmeier S, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells by high-dose cyclophosphamide and granulocyte colony-stimulating factors in patients with multiple myeloma. Br J Haematol 1997 98 : 736 44.
21. Weaver CH, Zhen B, Schwartzberg L, Walker C, Upton S, Buckner CD. A randomized trial of mobilization of peripheral blood stem cells with cyclophosphamide, etoposide, and granulocyte colony-stimulating factor with or without cisplatin in patients with malignant lymphoma receiving high-dose chemotherapy. Am J Clin Oncol 1998 21 : 408 12.
22. Akard LP, Wiemann M, Thompson JM, Swinney M, Lynn K, Hanks S, Jansen J. Impaired stem cell collection by consecutive courses of high-dose mobilization chemotherapy using cyclophosphamide, etoposide, and G-CSF. J Hematother 1996 5 : 271 7.
23. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P, Thieblemont C, Durand B, Neidhardt-Berard EM, Samaha H, Rigal D, Coiffier B. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998 103 : 235 42.
24. Demirer T, Buckner CD, Storer B, Lilleby K, Rowley S, Clift R, Appelbaum FR, Storb R, Bensinger WI. Effect of different chemotherapy regimens on peripheral blood stem cell collection in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 1997 15 : 684 90.
25. Eriksson WA, Hultdin M. Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. Eur J Haematol 2004 73 : 263 8.
26. O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006 37 : 731 7.
27. Bjorkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K, Prentice G, Cavo M, Samson D, de Laurenzi A, Verdonck LF, Proctor S, Ferrant A, Sierra J, Auzanneau G, Troussard X, Gravett P, Remes K, Gahrton G. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT registry study. Leuk Lymphoma 1994 15 : 265 72.
28. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999 93 : 1858 68.
29. Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G, Bellavita P, Viero P, Comotti B, Barbui T, Rambaldi A. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation program in multiple myeloma. Br J Haematol 2002 116 : 202 10.
30. Sugrue MW, Williams K, Pollock BH, Khan S, Peracha S, Wingard JR, Moreb JS. Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000 39 : 509 19.
31. Dreger P, Kloss M, Peterson B, Haferlach T, Löffler H, Loeffler M, Schmitz N. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995 10 : 3970 8.
32. Rainer H, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W. Patient characteristics associated with successful mobilization and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994 83 : 3787 94.
33. Duggan PR, Gou D, Luider J, Auer I, Klassen J, Chaudhry A, Morris D, Glück S, Brown CB, Russell JA, Stewart DA. Predictive factors for long-term engraftment of autologous blood stem cells. Bone Marrow Transplant 2000 26 : 1299 304.
34. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996 5 : 213 26.
35. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, Liso V, Perrone T, Liso A. Poor mobilization is an independent prognostic factor in patients with malignant lymphoma treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006 37 : 719 24.
36. Keating S, Suciu S, De Witte T, Zittoun R, Mandelli F, Belhabri A, Amadori S, Fibbe W, Gallo E, Fillet G, Varet B, Meloni G, Hagemeijer A, Fazi P, Solbu G, Willemze R EORTC Leukemia Group; GIMEMA Leukemia Group. The stem cell mobilization capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003 17 : 60 76.
37. Blystad AK, Delabie J, Kvaloy S, Holte H, Vålerhaugen H, Ikonomou I, Kvalheim G. Infused CD34 cell dose, but not tumor cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004 125 : 605 12.
38. Stockerl-Goldstein KS, Reddy SA, Horning SJ, Blume KG, Chao NF, Hu WW, Johnston LF, Long GD, Strober S, Wong RM, Feiner RH, Kobler S, Negrin RS. Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000 6 : 506 12.
39. Bensinger W, Applebaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995 13 : 2547 55.
40. Dreger P, Klöss M, Petersen B, Haferlach T, Löffler H, Loeffler M, Schmitz N. Autologous progenitor cell transplantation: prior exposure to stem cell toxic drugs determines yield and engraftment of peripheral blood cell but not bone marrow grafts. Blood 1995 86 : 3970 6.
41. Haas R, Möhle R, Frühauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W. Patient characteristics associated with successful mobilization and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994 83 : 3787 95.
42. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996 335 : 91 7.
43. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ Medical Research Council Adult Leukaemia Working Party. High dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003 348 : 1875 83.
44. Pierelli L, Iacone A, Quaglietta AM, Nicolucci A, Menichella G, Benedetti Panici P, D'Antonio D, De Laurenzi A, De Rosa L, Fioritoni G, Indovina A, Leone G, Majolino I, Montuoro A, Scimé R, Torlontano G. Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: a multicenter retrospective study. Br J Haematol 1994 86 : 70 5.
45. Lee SM, Ryder WD, Clemons MJ, Morgenstern GR, Chang J, Scarffe JH, Radford JA. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1999 24 : 271 7.
46. Witzens-Harig M, Heilmann C, Hensel M, Kornacker M, Benner A, Hass R, Fruehauf S, Ho AD. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+ selected peripheral blood progenitor cells. Stem Cells 2007 25 : 228 35.
47. Barrett AJ, Ringdén O, Zhang MJ, Bashey A, Cahn JY, Cairo MS, Gale RP, Gratwohl A, Locatelli F, Martino R, Schultz KR, Tiberghien P. Effect of nucleated marrow cell dose on relapse and survival in identical twin transplantation for leukemia. Blood 2000 95 : 3323 7.
48. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wislöff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen H, Lamvik J, Löfvenberg E, Nesthus I, Rödjer S. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000 95 : 7 11.